Tvardi Therapeutics, Inc. Stockholders Equity

• Tvardi Therapeutics, Inc. showed an increase of +123.0% in Stockholders Equity from 2024 to 2025.
• This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2016: $71.80 million | Q1 2017: $29.27 million | Q2 2017: $109.22 million | Q3 2017: $99.07 million | Q1 2018: $72.10 million | Q2 2018: $73.08 million | Q3 2018: $149.53 million | Q1 2019: $114.52 million | Q2 2019: $99.55 million | Q3 2019: $211.89 million | Q1 2020: $160.47 million | Q2 2020: $140.93 million | Q3 2020: $127.85 million | Q1 2021: $230.46 million | Q2 2021: $203.47 million | Q3 2021: $207.19 million | Q1 2022: $204.12 million | Q2 2022: $204.42 million | Q3 2022: $184.82 million | Q1 2023: $136.60 million | Q2 2023: $108.93 million | Q3 2023: $85.64 million | Q1 2024: -$66.17 million | Q2 2024: -$73.07 million | Q3 2024: -$78.50 million | Q1 2025: -$100.63 million | Q2 2025: $32.93 million | Q3 2025: $27.87 million.
• Over the full 15 years of available data (2011 to 2025), Tvardi Therapeutics, Inc.'s Stockholders Equity has grown by 140.2%.
• Historical annual values: Fiscal year 2025: $20.95 million | Fiscal year 2024: -$91.13 million | Fiscal year 2023: -$62.06 million | Fiscal year 2022: $158.78 million | Fiscal year 2021: $227.52 million | Fiscal year 2020: $249.00 million | Fiscal year 2019: $186.71 million | Fiscal year 2018: $133.63 million | Fiscal year 2017: $86.78 million | Fiscal year 2016: $50.73 million | Fiscal year 2015: $105.04 million | Fiscal year 2014: $51.66 million | Fiscal year 2013: -$54.08 million | Fiscal year 2012: -$58.13 million | Fiscal year 2011: -$52.06 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026